| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
United States Transuranium and Uranium Registries, Washington State University, Richland, Washington 99352 [S. B.], and Battelle Pacific Northwest National Laboratory, PO Box 999, Richland, Washington 99352 [B. D. T., R. A. G., D. L. M.]
The potential for gene transfection during shock wave tumor therapy was evaluated by searching for shock wave-induced DNA transfer in mouse tumor cells. B16 mouse melanoma cells were cultured by standard methods and implanted s.c. in female C57BL/6 mice 10–14 days before treatment. A luciferase reporter vector was used as the DNA plasmid for intratumoral injection at 0.2 mg/ml tumor. Air at 10% of tumor volume was injected after the DNA in some tumors to enhance acoustic cavitation activity. The shock wave generation system was similar to a Dornier HM-3 lithotripter with pressure amplitudes of 24.4 MPa peak positive and 5.2 MPa peak negative. Luciferase production in isolated tumor cells was measured with a luminometer 1 day after treatment to assess gene transfer and expression. Exposure to 800 shock waves, followed by immediate isolation and culture of tumor cells for 1 day, yielded 1.1 (0.43 SE) pg/106 cells for plasmid injection only and 7.5 (2.5 SE) pg/106 cells for plasmid plus air injection. Significantly increased luciferase production, relative to shams, occurred for 200-, 400-, 800-, and 1200-shock wave treatments with plasmid and air injection. Exposure with the isolation of tumor cells delayed for a day to allow gene expression within the growing tumors gave increased luciferase production for 100- and 400-shock wave exposures without and with air injection. Gene transfer therefore can be induced during lithotripter shock wave treatment in vivo, particularly with enhanced acoustic cavitation, which supports the concept that gene and shock wave therapy might be advantageously merged.
1 Supported by NIH Grant CA42947.
2 To whom requests for reprints should be addressed, at Battelle Pacific Northwest National Laboratory, P. O. Box 999, Richland, WA 99352.
Received 9/ 3/97. Accepted 12/ 1/97.
This article has been cited by other articles:
![]() |
W. Hundt, E. L. Yuh, M. D. Bednarski, and S. Guccione Gene Expression Profiles, Histologic Analysis, and Imaging of Squamous Cell Carcinoma Model Treated with Focused Ultrasound Beams Am. J. Roentgenol., September 1, 2007; 189(3): 726 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. F. W. Alton and on behalf of the United Kingdom Cystic Fibrosis Ge Use of Nonviral Vectors for Cystic Fibrosis Gene Therapy Proceedings of the ATS, December 1, 2004; 1(4): 296 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li, K. Tachibana, M. Kuroki, and M. Kuroki Gene Transfer with Echo-enhanced Contrast Agents: Comparison between Albunex, Optison, and Levovist in Mice--Initial Results Radiology, November 1, 2003; 229(2): 423 - 428. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |